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BACKGROUND: There is an increasing interest in designing decision tools [decision support technologies (DSTs)]
that support patients when they have to decide about health matters. The purpose of this review was to describe
and evaluate existing DSTs for amniocentesis testing. METHODS: Ten medical and psychological databases were
searched up to January 2008 and key authors and organizations contacted to identify DSTs for amniocentesis (pub-
lished or otherwise). DSTs that described amniocentesis testing were included. RESULTS: Six DSTs met the inclusion
criteria and were evaluated using the International Patient Decision Aids Standards Instrument. The evaluation
suggested that most DSTs provided a satisfactory level of information on the index decision and, on the specific fea-
tures of a diagnostic test; provided structured guidance in making a decision; were based on scientific evidence and
disclosed the funding sources and authors’ credentials. However, most DSTs failed to communicate probabilistic
information, to clarify patient values and use plain language. The majority of DSTs did not use a systematic develop-
ment process. Furthermore, the DSTs’ evaluation often lacked scientific rigour. In most cases, neither the quality nor
the effectiveness of the DST could be inferred from the evaluations. CONCLUSIONS: The review highlights variations
in the development, evaluation and quality of existing DSTs for amniocentesis. We do not know what impact DSTs
may have when implemented in clinical settings. Decisions in this context have high stakes and strong emotional
impacts. It is important to ensure that DSTs achieve high standards.
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Introduction
Women need to be informed about the benefits and potential harms
of diagnostic procedures such as amniocentesis. Amniocentesis is
a procedure to remove a small sample of amniotic fluid from the
amniotic sac surrounding the fetus in the womb. It is the most
common method of obtaining fetal cells for karyotyping and is
usually conducted after 15 weeks of pregnancy. Amniocentesis
carries a risk of miscarriage; the most often quoted rate is one mis-
carriage per 100 procedures (Papantoniou et al., 2001) and may
lead to a decision to terminate the pregnancy (Asch, 1999). The
decision to undertake amniocentesis is generally preceded by the
decision to undertake prenatal screening tests.
Prenatal screening tests, i.e. ultrasound scan (nuchal translu-
cency scan) or blood tests (maternal serum screening tests), deter-
mine the woman’s chance of having a baby affected by Down’s
syndrome. The British National Health Service offers maternal
serum screening tests (triple tests, quadruple tests, integrated
tests or combined tests) for Down’s syndrome to all women
between 15 and 18 weeks of pregnancy (Weisz and Rodeck,
2006). About 5–10% of women who undertake second-trimester
maternal serum screening test receive a high-risk (of abnormality)
result and are offered amniocentesis (Benn et al., 2006; Gidiri
et al., 2007). Any pregnant woman undertaking prenatal screening
for Down’s syndrome may have to decide about amniocentesis and
face the consequences this might have on her pregnancy, life and
family. The decisions to have prenatal screening and amniocent-
esis testing are closely related. Expectant parents should be
informed about the benefits, potential harms and implications of
invasive diagnostic procedures such as amniocentesis before
embarking on prenatal screening. Research shows that pregnant
women commonly undertake screening tests for Down’s syn-
drome without realizing they could be offered an amniocentesis,
receive a diagnostic of chromosomal abnormality and/or be
offered a termination of pregnancy (Jaques et al., 2004; Dormandy
et al., 2006).
The decision to undertake prenatal screening tests along with
the anxiety subsequent to an indication of high risk have been
extensively documented in the literature (Santalahti et al., 1998;
Michie et al., 1999; Wildschut et al., 2006). However, the amnio-
centesis decision has been commonly confounded with the
decision to undertake prenatal screening tests. As amniocentesis
is only offered to a minority of women who have prenatal screen-
ing tests, it has rarely been at the centre of the investigation. Yet,
the decision to undergo amniocentesis has risks and may therefore
be distressing, emotionally charged (Sarkar et al., 2006) and needs
to be undertaken in a short timeframe.
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Deciding about amniocentesis should be determined by the
expectant parents’ awareness of the purposes of the test, their atti-
tudes to the risks involved and how possible harms and benefits are
valued and evaluated. Difficult decisions such as these should
involve patients in choosing the option that is consistent with
their knowledge, values and long-term goals. In addition, the
decision to undertake amniocentesis is especially relevant in infer-
tile populations. Pregnant women who have had in vitro fertiliza-
tion are twice as likely to be offered amniocentesis after prenatal
screening tests (Wald et al., 1999; Benn et al., 2006). This decision
therefore affects a significant proportion of the couples who
undergo infertility treatments.
Toachieve these goals, technologies that support individualswhen
they face difficult decisions for themselves or others in their families
are being developed. Decision support technologies (DSTs), also
known as decisions aids (O’Connor et al., 2003) provide information
about available options and their associated harms, benefits and out-
comes in a variety of clinical contexts. The number of published
DSTs has tripled since 1999 (O’Connor et al., 2007). DSTs are
intended to help individuals learn about the features, issues and
implications of their treatment or screening options while improving
communication and open discussion with their health professionals.
Most of these interventions are developed in a practical manner and
use awide range ofmedia.DSTshave been noted to achieve different
levels of clinical effectiveness and to impact on several decision out-
comes (Entwistle et al., 1998).According to theCochrane systematic
review for people facing health treatment or screening decisions
(O’Connor et al., 2003), DSTs that have been evaluated in trials
improve knowledge as well as the agreement between personal
values and the choice made, increase active participation in decision
making and decrease decisional conflict.
To date, DSTs for amniocentesis have not been formally
reviewed nor evaluated. In the literature, attention has been pri-
marily focused on the decision to undertake screening tests
rather than on the decision to undergo invasive diagnostic tests
such as amniocentesis (Van den Berg et al., 2005; Weisz and
Rodeck, 2006; Garcia et al., 2008). Furthermore, reviews had
shown that there was limited research on how best to provide
information on amniocentesis testing (Green et al., 2004; Hunt
et al., 2005; Van den Berg et al., 2006). The aim of this study
was to identify, describe and assess the quality and effectiveness
of DSTs for amniocentesis and examine to what extent they
were used in clinical practice.
To meet our aims, the review was organized around three
questions:
(i) How many DSTs for amniocentesis exist and what are
their aims?
(ii) Do DSTs for amniocentesis meet published quality
standards?
(iii) What is the effectiveness of DSTs for amniocentesis?
Materials and Methods
Definitions
For the purpose of the review, DSTs were defined as: ‘Interventions
designed to help people make specific and deliberative choices
among options by providing information on the options and outcomes
relevant to a person’s health status’ (O’Connor et al., 2003). Further,
four essential criteria allowing the distinction between information
leaflets and DSTs were identified in the Cochrane review (O’Connor
et al., 2003) and in the domains and items of the International
Patient Decision Aids Standards Instrument (IPDASi) (Elwyn et al.,
2006). To be classified as a DST, an intervention should:
(i) state the decision to be addressed and deliberated upon,
(ii) provide information about the options, their harms, benefits
and the associated probabilities of the decision outcomes,
(iii) allow patients to express and clarify their values, attitudes,
preferences with regard to the decision,
(iv) provide structured guidance in coming to a decision
(step-by-step way to make a decision).
Two out of the four criteria (criteria 1 and 2) were used in select-
ing the DSTs for review. Accordingly, interventions that stated
that to have amniocentesis was the key decision to be considered
and provided information about the harms, benefits and outcomes
probabilities associated with each option were included in the
review.
Literature search strategy
Ten electronic databases were searched until January 2008: medline
(1966–2008), Medline In-Process (January 2008), PubMed (2008),
Embase (1980–2008), British Nursing Index (1994–December
2007), CINAHL (1982–December 2007), all EBM Reviews (2008),
PsycINFO (1806–2008), Science Citation Index Expanded (1970–
2008) and Social Sciences Citation Index (1970–2008). A list of
key words and subject headings (MeSH words in PubMed) was
written in Ovid in order to be combined and run in each database
(see Table I). DSTs for amniocentesis where reports have not been
published in peer-reviewed journals or have not been evaluated in a
trial were identified through manual check of reference lists from pub-
lished papers, internet search and manual check of the A–Z list of
decision aids developed by the Ottawa Health Decision Centre
(http://decisionaid.ohri.ca/AZinvent.php). All major DST developers
such as the Ottawa Health Decision Centre, Healthwise, Mayo Clinic,
Midwives Information and Resource Service (MIDIRS), Foundation
for Informed Medical Decision Making (FIMDM) and Intelihealth
(Harvard Medical School) were contacted.
Table I. Literature search strategy.
Amniocentesis DST
Amniocentesis Decision support technique
Prenatal diagnosis Patient decision aid
Antenatal diagnosis Decision aid
Prenatal testing Decision explorer
Antenatal testing Decision tool
Decision support
Decision
Decision making
Software
Decision support systems
Computer assisted
Information systems
Computer assisted decision support systems
Genetic counselling
All terms in the first column were combined with terms in second column.
Durand et al.
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Study inclusion and exclusion criteria
First, studies were included if they (i) considered DSTs that focused on
the decision to undertake amniocentesis (regardless of age and
pathway of entry) or (ii) considered the decision to undertake amnio-
centesis as well as other prenatal screening tests or other available
diagnostic tests such as chorionic villus sampling (CVS). CVS is a
procedure to remove a small amount of tissue from the placenta to
test the tissue in the laboratory and check for chromosomal abnormal-
ities (Brun et al., 2003). CVS is generally conducted between 11 and
14 weeks of pregnancy and carries a 2% risk of miscarriage (Caughey
et al., 2006).
Second, only interventions that were classified as DSTs, as opposed
to information leaflets, were included in this review (as described, see
Definitions section).
Studies were excluded if they (i) considered DSTs that exclusively
focused on prenatal screening tests or CVS without addressing the
decision to undertake amniocentesis and (ii) addressed a choice
between amniocentesis and CVS (see Fig. 1).
DST assessment
After having identified interventions that met our inclusion criteria, we
contacted the DST developers to obtain a copy of the DST and infor-
mation on its current use and implementation in clinical settings.
Information about the three aspects of DSTs was collected in order
to address our research questions.
First, a content analysis of the DSTs was carried out using the
IPDASi in order to quantify the quality of DSTs components for
amniocentesis. The IPDASi (www.ipdasi.org) is currently being vali-
dated (Elwyn et al., 2008) by an international group of researchers
working to assess the quality of DSTs (Elwyn et al., 2006). The
author was trained to perform IPDASi ratings before assessment.
IPDASi is a set of 48 quality criteria (or items) addressing
10 domains: information, test, probabilities, values, guidance,
development, evidence, disclosure, plain language and evaluation.
The ‘information’ domain assesses the quality of information provided
on the index decision, the options available and the positive and nega-
tive features of each option (eight items). The ‘test’ domain assesses
the extent to which specific features of the diagnostic or screening
investigation (e.g. rate of false positive or false negative test results)
are described in the DST (nine items). The ‘probabilities’ domain
evaluates the way in which probabilistic information is presented
and framed (eight items). The ‘values’ domain assesses whether the
DST facilitates the expression and clarification of the expectant
parents values in regards to the decision (five items). The ‘guidance’
domain investigates whether the DST provides structured guidance
in helping expectant parents come to a decision (two items). The
‘development’ domain appraises the quality of the DST’s develop-
ment process which should ideally involve professional/parents
needs assessment, expert review and field-testing (six items). Field
testing consists of showing the DST to potential users (expectant
parents) who comment on its content and usability in order to
amend the DST accordingly. The ‘evidence’ domain assesses the
quality of the research evidence used in developing the DST (five
items). The ‘disclosure’ domain appraises the transparency of the
funding and author disclosure (two items). The ‘plain language’
domain assesses the DST clarity and readability levels (one item).
Finally, the ‘evaluation’ domain assesses the impact of the DST on
decision outcomes (one item). Each item was rated on a scale from
1 ¼ strongly disagree to 4 ¼ strongly agree. Domain and total
IPDASi percentage scores were calculated by summing relevant
items and dividing by the number of items per domain, which
accounted for the unequal number of items per domain.
It has been found that the majority of DSTs are developed without
theoretical foundations (Durand et al., 2008). We therefore examined
the use of theory in the development of DSTs for amniocentesis by
reviewing the relevant publications and by contacting the DST devel-
opers to determine whether theory had been used in the development
Figure 1: Decision support technology search of 10 databases.
Decision tools for amniocentesis
661
 at K
atholieke U
niversiteit on July 12, 2012
http://hum
upd.oxfordjournals.org/
D
ow
nloaded from
 
process. The efficacy of the DSTs was determined by assessing
evaluation methods and outcomes. Finally, we examined the current
use and implementation of the DSTs in clinical settings.
Results
Selection of DSTs
The literature search and contact with authors identified 11 inter-
ventions (Fig. 1). After assessment of their content and/or related
available publications, five interventions were excluded. Three
DSTs did not focus on the decision to undertake amniocentesis.
The DST by Heckerling et al. was excluded because it compares
amniocentesis testing and CVS (Heckerling et al., 1994, 1999;
Verps and Heckerling, 1995). The DSTs by Harris et al. (2001)
and Kuppermann et al. (2004) were excluded because they focus
on prenatal screening tests without specifically addressing the
decision to undertake amniocentesis. Two interventions failed to
be classified as DSTs (did not meet criteria 1 and 2 of Definitions
section) and were identified as information leaflets after content
analysis. These two are the web-based intervention produced by
InteliHealth (2005) and the information leaflet produced by
MIDIRS: ‘Is my baby alright?’ (MIDIRS, 2005).
How many DSTs for amniocentesis exist and what are their aims?
Six DSTs for amniocentesis were examined in the review: (i)
A Decision Analytic Consultation by Bekker et al. (2004), (ii) a
DST developed by Drake et al. combining an audiotape and a
booklet entitled Making Choices: Prenatal Testing (Drake et al.,
1999; Hunter et al., 2005), (iii) The Amniocentesis Report, a
booklet downloaded from the internet produced by Ferber and
Sicherman (2001), (iv) a web-based DST for amniocentesis deve-
loped by the Healthwise group entitled Should I have an amnio-
centesis? (Healthwise, 2006), (v) a DST for prenatal testing
developed by Nagle et al. (2008) and (vi) a decision analytic
model developed by Pauker and Pauker (1979, 1987). Of the six
DSTs identified, three were developed in the USA (Pauker and
Pauker, 1979; Ferber and Sicherman, 2001; Healthwise, 2006),
one in Canada (Drake et al., 1999), one in Australia (Nagle
et al., 2008) and one in the UK (Bekker et al., 2004). Two out
of the six interventions were available on internet (Ferber and
Sicherman, 2001; Healthwise, 2006), although one of the DSTs’
availability was subjected to payment (Ferber and Sicherman,
2001). On the basis of the Ottawa A–Z inventory and contact
with authors, it was ascertained that two of the six DSTs were
used in 2007/2008 in clinical settings: Pauker’s decision analysis
consultation (Pauker and Pauker, 1979) and the DST for prenatal
testing of fetal abnormalities produced by Nagle et al. (2008).
Pauker’s decision analysis consultation is used in routine genetic
counselling at Harvard Vanguard Medical Associates across
eastern MA, USA. The DST by Nagle et al. is used by maternity
care clinicians as part of a state-wide education program in
Victoria, Australia. The interventions are listed in Table II and
described according to their name, decision considered, format,
accessibility and use, theoretical framework used in developing
the DST and outcome measurements (when applicable).
The six DSTs varied in their content and approach. The decision
analysis consultation developed by Bekker et al. (2004) is based on
Pauker and Pauker’s decision analytic model. Its aim is to help
parents clarify and express their values with regard to the decision
and balance those values against the risks involved (i.e. risk of mis-
carriage, risk of chromosome abnormality). The presentation of
information is structured around the test options (accepting/declin-
ing amniocentesis), potential consequences (harms or benefits) and
associated outcome probabilities. The consultation is articulated
around the use of a decision tree displaying test options and conse-
quences, and a ‘lottery technique’ designed to facilitate a trade off
between options and elicit themaximum ‘utility’ (the ‘goodness’ of
each option and associated consequences). The lottery technique
consists of asking questions to compare the options (accepting or
declining amniocentesis) on each attribute (e.g. chance of having
a baby with Down’s syndrome) by varying the ‘gamble figure’:
‘If we told you the chance of the baby having Down’s syndrome
was fifty per cent, and the chance of the baby not having Down’s
syndrome was fifty per cent, would you choose to carry on with
or terminate the pregnancy?’ (Bekker et al., 2004). Finally, a
graph combining the couple’s ‘best utility’ and the results of the
maternal serum screening test (adjusted chance of having a baby
with Down’s syndrome) is used to identify the option with
the greatest ‘expected utility’. From a ‘rational’ standpoint, the
option with the highest expected value corresponds to the best
possible option for that couple.
The DST by Drake et al., Making a choice: prenatal testing
(Drake et al., 1999; Hunter et al., 2005), provides information
about maternal serum screening tests, ultrasound scans, CVS
and amniocentesis testing. Its goal is to improve knowledge,
decrease decisional conflict (uncertainty), and decrease anxiety
levels associated with prenatal testing. The DST consists of a
35-page illustrated workbook, a 45 min audiotape and a work-
sheet. The worksheet gives expectant parents the opportunity to
clarify the reasons for undertaking or declining prenatal tests
and provides a concrete basis for discussing the options with
health professionals.
The amniocentesis report by Ferber et al., A Decision Guide for
Expectant Parents and Healthcare Professionals, consists of a
16-page booklet providing structured information on amniocent-
esis testing, its potential risks and implications. It aims to
provide accurate unbiased information on amniocentesis and
help expectant parents decide whether or not to undergo amnio-
centesis. The booklet can be downloaded from the internet or
ordered as a hard copy. The DST is divided into six sections:
(i) What is amniocentesis and how is it done, (ii) Nature and accu-
racy of the amniocentesis results, (iii) What are the benefits of
amniocentesis, (iv) What are the costs of amniocentesis (relevant
to the USA), (v) Making the amniocentesis decision and (vi)
Alternative procedures. The DST does not explicitly enable preg-
nant women/couples to clarify their values with regard to the
decision.
The web-based DST produced by Healthwise is an interactive
website entitled Should I have An Amniocentesis. The DST
intends to help expectant parents understand their choices regard-
ing amniocentesis testing. The DST includes four sections (intro-
duction, medical information, your information and wise health
decision) and is equivalent to seven printed pages. The third
section ‘your information’ compares the reasons to have or to
decline amniocentesis, whereas the last section ‘a wise health
decision’ provides a worksheet for patients to clarify their ideas
and values with regard to the amniocentesis decision.
Durand et al.
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Table II. DST characteristics.
Authors Name of DST Decision Format, use and access Theoretical
framework
Outcome measures
Bekker et al. (2004) Decision analysis
consultation
Prenatal diagnostic test
(amniocentesis and CVS)
Routine consultation structured by decision analysis Decision analysis Consultation length
Method used in an additional information consultation
offered to women after they received a screen-positive
maternal serum screening test result for Down syndrome
Informed decision-making
DST developed in the UK Test choice
Drake et al. (1999)
Hunter et al. (2005)
Making choices Prenatal testing Workbook and audiotape Ottawa decision
support framework
Knowledge
Prenatal testing –Maternal serum screening DST used is a genetic counselling consultation and
includes a discussion with a genetic counsellor
Anxiety
–Amniocentesis DST developed in Canada Decisional conflict
–Chorionic villus sampling Intervention satisfaction
Ferber and Sicherman
(2001)
The amniocentesis report Amniocentesis Testing Web-based DST No theory No evaluation
‘Decision guide for
expectant parents and
health care professionals’
www.amniocentesis.org
DST can be downloaded in PDF format online or shipped
worldwide
Minimal fee: $5.05
DST developed in the USA
Healthwise (2006,
last update)
Should I have an
amniocentesis?
Amniocentesis testing Web-based DST No theory No evaluation
www.webmd.com/baby/should-i-have-an-amniocentesis
Open Access
(free of charge)
DST developed in the USA
Nagle et al. (2006) A Decision aid for
Prenatal Testing of fetal
abnormalities
Prenatal testing: 24-page booklet Ottawa decision
support framework
Informed choice
–Maternal serum screening Decisional conflict
–Second trimester ultrasound
scan
DST given to women in early pregnancy by their GP Anxiety
–Chorionic villus sampling DST developed in Australia Depression
Attitudes to the fetus/
pregnancy
Satisfaction with the DST
Pauker and Pauker
(1979)
A decision analytic
model to counsel patient
about amniocentesis
Amniocentesis Testing Routine consultation structured by decision analysis Decision analysis Assessed cost of elective
miscarriage
Method used in a routine genetic counselling session for
prenatal diagnosis
Assessed cost of spontaneous
miscarriage
Actual decision
DST developed in the USA Decision suggested by
decision analytic model
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The DST for prenatal testing by Nagle et al. (2008) is a 24-page
booklet containing varied graphical design elements (diagram,
images, charts and dot points) and information about maternal
serum screening, second-trimester ultrasound scan, CVS and
amniocentesis testing. The DST aims to assist women in making
an informed choice about amniocentesis and reduce decisional
conflict. It provides information on the reasons for being offered
testing, the range of prenatal tests available and the results and
implications of such tests. The DST contains scenarios of
women’s experience when deciding about testing, a worksheet
to weigh up the pros and cons of each option and a list of
further information resources available. Finally, it includes a
risk-report sheet presenting the risk estimates of having a baby
affected with Down’s syndrome, based on the expectant
mother’s age and gestation.
The decision analytic DST developed by Pauker and Pauker
(1979) is used to counsel patients about amniocentesis testing.
The DST was designed to help parents assess their values and atti-
tudes about the outcomes of options and make a logical decision
(guided by decision analysis) about amniocentesis. The decision
analytic DST uses a lottery technique and considers the following
outcomes: miscarriage, detection of chromosomal abnormality
and being faced with diagnostic errors. Prospective parents are
asked to assign a utility (on a scale from 0 to 100) to the potential
outcomes of both available options: undertaking or declining
amniocentesis.
Do DSTs for amniocentesis meet published quality standards?
IPDAS evaluation criteria
Five out of the six DSTs were rated against all IPDAS domains to
assess their quality (Table III). The evaluation of one DST (Nagle
et al., 2008) was exclusively based on the publications since the
developers declined to provide a copy of the intervention.
The provision of different types of information was variable
across domains. Scores on the ‘information’ domain reached
73.7% on average. Most DSTs for amniocentesis showed very
little variation regarding the provision of information. Scores on
the ‘test’ domain (evaluating the specific features of a diagnostic
test) were on average lower (61.6%) than scores on the infor-
mation domain. Three DSTs (Ferber and Sicherman, 2001;
Bekker et al., 2004; Healthwise, 2006) did not include full infor-
mation on the false positive and false negative results associated
with the tests and scored significantly lower than other DSTs
evaluated. Scores on the ‘probabilities’ domain reached 55% on
average. Most DSTs provided very little information about the
outcome probabilities associated with the options. Scores on the
‘plain language’ domain reached 40% on average. Most DSTs
did not use plain language throughout and did not report readabi-
lity levels.
There were also IPDASi score differences in domains clarifying
factors and ways of making the decision. The average score on the
‘values’ domain was 53%. Three interventions only (Drake et al.,
1999; Bekker et al., 2004; Healthwise, 2006) explicitly enabled
parents to express and clarify their values. In contrast, average
scores on the ‘guidance’ domain reached 80%. Three DSTs
(Drake et al., 1999; Bekker et al., 2004; Healthwise, 2006)
reached the highest score by providing ‘a step-by step way to T
a
b
le
II
I.
D
S
T
s
ra
te
d
o
n
th
e
In
te
rn
at
io
n
al
P
at
ie
n
t
D
ec
is
io
n
s
A
id
s
S
ta
n
d
ar
d
s
(I
P
D
A
S
)
in
st
ru
m
en
t.
N
am
e
o
f
IP
D
A
S
i
D
o
m
ai
n
s
N
am
e
o
f
D
S
T
(i
)
D
ec
is
io
n
an
al
y
si
s
co
n
su
lt
at
io
n
B
ek
k
er
et
a
l.
(2
0
0
4
)
(i
i)
M
ak
in
g
ch
o
ic
es
:
p
re
n
at
al
te
st
in
g
D
ra
k
e
et
a
l.
(1
9
9
9
)
H
u
n
te
r
et
a
l.
(2
0
0
5
)
(i
ii
)
T
h
e
am
n
io
ce
n
te
si
s
re
p
o
rt
F
er
b
er
an
d
S
ic
h
er
m
an
(2
0
0
1
)
(i
v
)
S
h
o
u
ld
I
h
av
e
an
am
n
io
ce
n
te
si
s?
H
ea
lt
h
w
is
e
(l
as
t
u
p
d
at
e
2
0
0
6
)
(v
)
A
d
ec
is
io
n
an
al
y
ti
c
m
o
d
el
to
co
u
n
se
l
p
at
ie
n
t
ab
o
u
t
am
n
io
ce
n
te
si
s
P
au
k
er
an
d
P
au
k
er
(1
9
7
9
)
A
v
er
ag
e
sc
o
re
s
p
er
d
o
m
ai
n
In
fo
rm
at
io
n
6
8
.7
a
7
5
.0
6
5
.6
8
4
.4
7
5
.0
7
3
.7
T
es
t
5
5
.5
6
3
.9
5
5
.5
5
0
.0
8
3
.3
6
1
.6
P
ro
b
ab
il
it
ie
s
6
5
.6
5
6
.2
4
3
.7
4
0
.6
6
8
.7
5
5
.0
V
al
u
es
5
5
.0
7
5
.0
3
5
.0
5
5
.0
4
5
.0
5
3
.0
G
u
id
an
ce
1
0
0
.0
1
0
0
.0
5
0
.0
1
0
0
.0
5
0
.0
8
0
.0
D
ev
el
o
p
m
en
t
5
8
.3
5
0
.0
4
5
.8
3
3
.3
6
6
.7
5
0
.8
E
v
id
en
ce
8
0
.0
6
0
.0
4
0
.0
9
5
.0
5
5
.0
6
6
.0
D
is
cl
o
su
re
7
5
.0
7
5
.0
6
2
.5
8
7
.5
6
2
.5
7
2
.5
P
la
in
la
n
g
u
ag
e
5
0
.0
5
0
.0
2
5
.0
5
0
.0
2
5
.0
4
0
.0
E
v
al
u
at
io
n
1
0
0
.0
1
0
0
.0
2
5
.0
2
5
.0
5
0
.0
6
0
.0
A
v
er
ag
e
sc
o
re
s
p
er
D
S
T
7
0
.8
7
0
.5
4
4
.8
6
2
.1
5
8
.1
a
S
co
re
s
o
n
th
e
IP
D
A
S
in
st
ru
m
en
t
in
p
er
ce
n
ts
.
Durand et al.
664
 at K
atholieke U
niversiteit on July 12, 2012
http://hum
upd.oxfordjournals.org/
D
ow
nloaded from
 
make a decision’, and worksheets designed to structure the expec-
tant parents’ decision-making process.
IPDASi scores concerning the process of DST development and
evaluation were in the mid to higher range. On the ‘development’
domain scores reached 50.8% on average. The development
process generally lacked rigour and rarely involved expectant
parents. According to the IPDAS standards, the development
process should ideally involve a needs assessment with expectant
parents and professionals, the parents and professionals review of
the DST and field testing before evaluation. Most DSTs were
based on literature reviews, reviewed by researchers or occasion-
ally health professionals and omitted expectant parents’ needs
assessment or review. Finally, only two out of the six DSTs
were explicitly field tested with patients (Drake et al., 1999;
Nagle et al., 2008). Scores on the ‘evidence’ domain (assessing
the scientific validity of the DST) reached 66% on average. The
development of three DSTs (Drake et al., 1999; Bekker et al.,
2004; Healthwise, 2006) was explicitly based on research evi-
dence (i.e. citations to studies used). Scores on the ‘evaluation’
domain reached 60% on average. Four DSTs (Pauker and
Pauker, 1987; Drake et al., 1999; Bekker et al., 2004; Nagle
et al., 2008) were evaluated in a trial, including the DST by
Nagle et al. (2008). Two DSTs out of the three (Drake et al.,
1999; Bekker et al., 2004) were reported to help patients make a
decision that was ideally consistent with their values and pre-
ferences. Finally, most DSTs acknowledged sponsors and con-
tributors. The average score on the ‘disclosure’ domain was
72.5%. All DSTs reached high scores on this domain by displaying
funding information and credentials of those developing the DST.
Theoretical foundation
Four out of the six interventions mentioned the contribution of a
theoretical framework in developing the DST (Pauker and
Pauker, 1987; Drake et al., 1999; Bekker et al., 2004; Nagle
et al., 2008). Decision analysis (expected utility theory) guided
the design and use of two DSTs for amniocentesis (Pauker and
Pauker, 1979; Bekker et al., 2004). Two DSTs (Drake et al.,
1999; Nagle et al., 2008) relied on the Ottawa decision support
framework (O’Connor et al., 1999). The Ottawa decision
support framework combines social support and cognitive psy-
chology theories such as the expectancy value model (Fishbein,
1975), prospect theory (Kahneman and Tversky, 1979), the con-
flict theory model of decision-making (Janis and Mann, 1977)
and the theory of reasoned action (Fishbein, 1975). There is as
yet no evidence about the influence that theory-based design has
on outcomes. However, two out of the three ‘theory based’
DSTs (Drake et al., 1999; Bekker et al., 2004) have higher
IPDASi scores (70.8 and 70.5) than DSTs that do not rely on
theory.
What is the effectiveness of existing DSTs?
Three out of the six DSTs were evaluated using randomized con-
trolled trials (Bekker et al., 2004; Hunter et al., 2005; Nagle et al.,
2006). One DST was evaluated in a pilot study (Pauker and
Pauker, 1979).
The decision analysis DST by Bekker et al. was evaluated in a
randomized controlled trial of 117 women offered amniocentesis
testing and randomized to a routine consultation or a decision
analysis consultation. The risk perception of the screening test
result, subjective utility (generated by the decision analytic
method), knowledge, consultation quality, decisional conflict
and anxiety were measured. The intervention reduced decisional
conflict, improved informed decision-making and led to a more
realistic evaluation of information. However, the DST was
unable to predict the final decision: the decision suggested by
the decision analysis was inconsistent with the decision that
parents finally made. The DST did not significantly impact on con-
sultation satisfaction, knowledge nor reduced anxiety when com-
pared with the control group. The latter finding is consistent
with the results of similar evaluations (O’Connor et al., 2003).
The DST by Drake et al. (Drake et al., 1999; Hunter et al., 2005)
was evaluated in a randomized controlled trial of three counselling
methods for prenatal diagnostic (Hunter et al., 2005) and one
pre-to-post study (Drake et al., 1999). First, a randomized con-
trolled trial of three counselling methods for prenatal diagnosis
(individual counselling, group counselling and use of a DST by
Drake et al.) assessed the following outcomes measures: know-
ledge, state-trait anxiety, decisional conflict and intervention satis-
faction in a sample of 350 women (and 225 partners) who had been
offered prenatal diagnostic testing because of advanced maternal
age (Hunter et al., 2005). Compared with other counselling
methods (group and individual counselling), the DST was least
efficient at improving prospective parents knowledge (although
knowledge increased compared with the pre-counselling phase).
The DST did not significantly diminish state anxiety. However,
decisional conflict was significantly reduced. The satisfaction
with the DST was high but not higher than alternative counselling
methods (i.e. group counselling). Second, the pre-to-post study
(Drake et al., 1999) evaluated the DST’s impact on knowledge,
decisional conflict, state-trait anxiety and intervention acceptabi-
lity in a sample of 21 women (and 17 partners). The DST was
reported to have significantly increased knowledge and decreased
decisional conflict but did not modify state anxiety level.
However, the findings were not compared with a control group.
The DST by Nagle et al., which was not available for IPDASi
rating, was evaluated in a cluster randomized controlled trial
where 55 general practitioners were randomized to provide
women (n ¼ 338) with the DST (intervention group) or a pamphlet
(control group). The following outcome measures were assessed:
informed choice and decisional conflict (primary outcome
measures), anxiety, depression, attitudes to the fetus/pregnancy
and satisfaction with the DST or pamphlet. The results showed
that more women made an informed choice when given the DST
than when given the pamphlet. The satisfaction with the inter-
vention was significantly higher in the intervention group (use of
DST). The level of decisional conflict was low in both intervention
and control groups. There were no significant differences on the
secondary outcomes: anxiety, depression or attitudes to the preg-
nancy/fetus.
The decision analysis DST by Pauker et al. was evaluated with
90 women (35 couples) who were offered amniocentesis. The
evaluation consisted of comparing women’s (or couples) attitudes
on miscarriage and termination of pregnancy. Most couples made
a decision that was consistent with their attitudes towards mis-
carriage and elective pregnancy termination. However, choices
made by some couples conflicted with their stated values. The
findings showed that the actual choice bore no relation to the
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choice suggested by the decision analysis. The reliability of the
findings could be questioned by the absence of a control group.
IPDASi scores reached a total average score of 58.1%.
Finally, two DSTs (Ferber and Sicherman, 2001; Healthwise,
2006) were not evaluated but low scores on IPDASi suggest
domains that could be improved (Table III). The amniocentesis
report produced by Ferber et al. scored the lowest on IPDASi
(total adjusted score: 44.8%). In brief, the evaluation of four out
of the six DSTs was of variable quality and did not result in signifi-
cant changes in the selected decision outcomes (knowledge,
anxiety and decisional conflict).
Discussion
Six DSTs for amniocentesis were identified; their quality was vari-
able and they did not score highly against recently developed stan-
dards. The evaluations conducted on the DSTs had considerable
scope for improvement. This reflects the emergent nature of this
field and highlights the need for a DST capable of addressing
parents’ information and decision support needs.
Existing DSTs for amniocentesis are a small proportion of the
total number of DSTs (over 500) developed in other healthcare
contexts worldwide (O’Connor et al., 2007), and there may be
several reasons to account for the scarcity of DSTs in this
medical context. First, deciding about amniocentesis might not
be perceived as generating as much anxiety and decisional conflict
as other screening or treatment decisions surrounding directly life-
threatening conditions. However, there is much evidence that
amniocentesis generates peak levels of anxiety, at a time of par-
ticular emotional vulnerability (Robinson et al., 1984; Sarkar
et al., 2006), and that such maternal stress could be associated
with poor outcomes (i.e. gestational complication, fetal growth
retardation) for the mother and fetus (Reading, 1983; Nakamura
et al., 2008). Second, the difficulty to assess the decision-making
process surrounding amniocentesis testing may account for the
small proportion of amniocentesis DSTs available. Only 1–5%
of women who undertake prenatal screening tests will be offered
an amniocentesis (Benn et al., 2006; Gidiri et al., 2007). The
number of women concerned with this decision is therefore few
and combined with high levels of stress and anxiety, it is difficult
to approach women at the early stage of the decision-making
process in order to gain the necessary data to inform DST develop-
ment. Finally, there is much variation in patient preference for sole
or shared decision-making (Schneider et al., 2006) and a lack of
DSTs in this highly emotive context. This may reflect the fact
that some patients prefer to hand over decision-making to their
physicians even though they ultimately must make the decision.
DSTs for amniocentesis are generally not used in routine clini-
cal practice. Interventions that are primarily developed by aca-
demics (lack of field testing and needs assessment) might be
unable to meet the practical requirements and decision support
needs of patients and professionals who are expected to use it
and would justify the consistent difficulty to implement DSTs
into practice (Holmes-Rovner et al., 2000; Silvia et al., 2008).
These results point to the need to develop DSTs that have better
goodness-of-fit with the clinical situations they are meant to
support.
The IPDASi evaluation emphasized the variable quality across
DSTs and domains. Most DSTs are effective and reliable
information resources because they provide adequate information
on the amniocentesis decision, on the features of a diagnostic test,
guide expectant parents in making a decision and use scientific
evidence. However, the communication of outcome probabilities,
the expression and clarification of values, the development
process, the evaluation and the use of plain language could be sig-
nificantly improved. Lower scores on those domains may reflect
the complexity and specialization of the domains’ requirements
combined with the recent development, inexperience and
implementation difficulties in the field of shared decision
making (and DSTs development). Our analysis subsequently
revealed that most DSTs had a theoretical origin, a finding incon-
sistent with existing DST reviews (Bekker et al., 1999; Bowen
et al., 2006; Durand et al., 2008).
The DSTs evaluations in trials of varying size and method
revealed poor quality experiments and pointed to the difficulty
to assess the DSTs’ effectiveness. The match between clearly
stated goals and the results of the evaluation was poor. In majority,
DSTs were shown to facilitate information processing but failed to
reduce emotional burdens associated with the amniocentesis
decision (e.g. anxiety) and could not predict actual decisions.
This may reflect a growing tendency to develop DSTs in short
timeframes and promote their use on internet without rigorously
evaluating their impact on decision-making outcomes. This
raises concerns as to the use of poor quality DSTs by expectant
parents who are expected to make high-stake decisions at a time
of considerable emotional upheaval.
The present study is the first to have reviewed DSTs for amnio-
centesis. However, systematic reviews conducted in other health-
care contexts (Williams et al., 2002; Evans et al., 2005; Volk et al.,
2007) corroborate our findings. Systematic reviews of prostate
cancer screening (Evans et al., 2005; Volk et al., 2007) revealed
that DSTs increased knowledge but did not impact on other
decision outcomes nor reduce emotional burdens. A systematic
review of interactive decision aids for breast cancer genetic
testing (Williams et al., 2002) supports the present findings by
identifying a very small number of poor quality interventions
rarely evaluated and available to users. The IPDASi scores of
DSTs for breast cancer genetic testing reached lowest scores on
the same domains as DSTs for amniocentesis (communication of
outcome probabilities, value expression and clarification, develop-
ment process and evaluation).
Strengths of the study were the comprehensive search and the
multidimensional analyses performed. Limitations need to be con-
sidered in interpreting the findings. All the evaluations, including
the IPDASi rating, were undertaken by a single researcher
(M.A.D.). However, decisions, especially those where uncertainty
arose, were discussed with co-authors to arrive at agreed
resolutions.
To conclude, few DSTs for amniocentesis are implemented in
practice and do not seem to provide sufficient decision support
for people facing this difficult decision (Hunt et al., 2005).
There is a need for further improvement of existing interventions.
The next generation of DST for amniocentesis should be guided by
the IPDAS criteria, using patient and professional involvement as
a central component to the DST development and rigorous field
test and evaluation should be conducted (Evans et al., 2007). Com-
pared with other healthcare contexts (breast cancer, heart disease),
little attention has been given to the decision to undertake
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amniocentesis, or other difficult decisions surrounding the area of
reproduction and infertility. Whether deciding about prenatal
testing or infertility treatments, the complexity of the information
provided, the high stakes of the decision, emotional strain and high
anxiety levels associated makes it difficult and distressing for
couples or expectant parents to engage in a decision-making
process. This emphasizes the need for high-quality DSTs.
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